DK1318785T3 - PULMONAL ADMINISTRATION OF L-DOPA - Google Patents
PULMONAL ADMINISTRATION OF L-DOPA Download PDFInfo
- Publication number
- DK1318785T3 DK1318785T3 DK01971210.8T DK01971210T DK1318785T3 DK 1318785 T3 DK1318785 T3 DK 1318785T3 DK 01971210 T DK01971210 T DK 01971210T DK 1318785 T3 DK1318785 T3 DK 1318785T3
- Authority
- DK
- Denmark
- Prior art keywords
- dopa
- particles
- administration
- oral
- pulmonary
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims description 180
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims description 180
- 239000002245 particle Substances 0.000 claims description 152
- 230000002685 pulmonary effect Effects 0.000 claims description 98
- 239000003814 drug Substances 0.000 claims description 56
- 208000018737 Parkinson disease Diseases 0.000 claims description 16
- 238000009118 salvage therapy Methods 0.000 claims description 15
- 230000009471 action Effects 0.000 claims description 9
- 229960004502 levodopa Drugs 0.000 claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 206010049119 Emotional distress Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000009429 distress Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 60
- 229960004538 alprazolam Drugs 0.000 description 51
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 51
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 48
- 210000004072 lung Anatomy 0.000 description 44
- 206010010904 Convulsion Diseases 0.000 description 41
- 241000700159 Rattus Species 0.000 description 41
- 230000000694 effects Effects 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 35
- 238000000034 method Methods 0.000 description 34
- 239000000843 powder Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 230000036470 plasma concentration Effects 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000001990 intravenous administration Methods 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 25
- 229960000991 ketoprofen Drugs 0.000 description 25
- 229960003638 dopamine Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 21
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 20
- 125000001931 aliphatic group Chemical group 0.000 description 20
- 239000000443 aerosol Substances 0.000 description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 230000008901 benefit Effects 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 150000003904 phospholipids Chemical class 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229960004205 carbidopa Drugs 0.000 description 12
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000003305 oral gavage Methods 0.000 description 11
- 238000001694 spray drying Methods 0.000 description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 10
- 239000001110 calcium chloride Substances 0.000 description 10
- 229910001628 calcium chloride Inorganic materials 0.000 description 10
- 229960004562 carboplatin Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002345 respiratory system Anatomy 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000001509 sodium citrate Substances 0.000 description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000003414 extremity Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003570 air Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 7
- 230000036765 blood level Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000003194 forelimb Anatomy 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000005913 Maltodextrin Substances 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- 229940112141 dry powder inhaler Drugs 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 5
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 5
- 229960004046 apomorphine Drugs 0.000 description 5
- 239000003954 decarboxylase inhibitor Substances 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 229960003299 ketamine Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010001541 Akinesia Diseases 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- -1 for example Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 238000011990 functional testing Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 210000001557 animal structure Anatomy 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002409 epiglottis Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- KLCWZYAIXXNWQH-UHFFFAOYSA-N C1C2=CC1CC2 Chemical compound C1C2=CC1CC2 KLCWZYAIXXNWQH-UHFFFAOYSA-N 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 101100156608 Mus musculus Vwde gene Proteins 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091092920 SmY RNA Proteins 0.000 description 1
- 241001237710 Smyrna Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- MBURIAHQXJQKRE-UHFFFAOYSA-M sodium;octane-1-sulfonate;hydrate Chemical compound O.[Na+].CCCCCCCCS([O-])(=O)=O MBURIAHQXJQKRE-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/665,252 US6514482B1 (en) | 2000-09-19 | 2000-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
| US09/877,734 US6613308B2 (en) | 2000-09-19 | 2001-06-08 | Pulmonary delivery in treating disorders of the central nervous system |
| PCT/US2001/029311 WO2002024158A2 (en) | 2000-09-19 | 2001-09-19 | Pulmonary delivery in treating disorders of the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1318785T3 true DK1318785T3 (en) | 2017-04-03 |
Family
ID=27099159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01971210.8T DK1318785T3 (en) | 2000-09-19 | 2001-09-19 | PULMONAL ADMINISTRATION OF L-DOPA |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US6613308B2 (enExample) |
| EP (2) | EP1318785B1 (enExample) |
| JP (2) | JP5421510B2 (enExample) |
| AU (2) | AU9112201A (enExample) |
| CA (1) | CA2421974C (enExample) |
| CY (1) | CY1118851T1 (enExample) |
| DK (1) | DK1318785T3 (enExample) |
| ES (1) | ES2621549T3 (enExample) |
| PT (1) | PT1318785T (enExample) |
| WO (1) | WO2002024158A2 (enExample) |
Families Citing this family (180)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US7779020B2 (en) * | 2002-03-01 | 2010-08-17 | International Business Machines Corporation | Small-footprint applicative query interpreter method, system and program product |
| ES2211151T3 (es) | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| CA2307278A1 (en) * | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
| FR2812545B1 (fr) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| WO2002094246A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| US6759029B2 (en) | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
| WO2002094232A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antidepressants through an inhalation route |
| US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
| WO2002094230A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of sedative-hypnotics trough an inhalation route |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| WO2002094244A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
| WO2002094238A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of anti-migraine compounds through an inhalation route |
| US6737042B2 (en) * | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| WO2002094233A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antiemetics through an inhalation route |
| WO2002094237A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of beta-blockers through an inhalation route |
| DK1389096T3 (da) * | 2001-05-24 | 2009-06-22 | Alexza Pharmaceuticals Inc | Indgivelse af opiater gennem en inhalationsrute |
| US20080038363A1 (en) * | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
| US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
| DE60230502D1 (de) * | 2001-05-24 | 2009-02-05 | Alexza Pharmaceuticals Inc | Verabreichung von antimigränemitteln durch inhalation |
| WO2002094218A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US7766013B2 (en) * | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| DE10137633A1 (de) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma | Pramipexol zur Behandlung von ADHD |
| WO2003041693A1 (en) * | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
| WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
| ES2364636T3 (es) | 2001-12-19 | 2011-09-08 | Novartis Ag | Administración pulmonar de aminoglucósidos. |
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| JP2005520847A (ja) * | 2002-03-20 | 2005-07-14 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 肺投与用ｈＧＨ（ヒト成長ホルモン）製剤 |
| PT2494962E (pt) * | 2002-03-20 | 2014-08-27 | Civitas Therapeutics Inc | Administração pulmonar de levodopa |
| JP2005529123A (ja) * | 2002-04-24 | 2005-09-29 | リサーチ ディベロップメント ファンデーション | 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果 |
| AU2003239433A1 (en) | 2002-05-13 | 2003-11-11 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| US20060193788A1 (en) * | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
| US20040101481A1 (en) * | 2002-11-26 | 2004-05-27 | Alexza Molecular Delivery Corporation | Acute treatment of headache with phenothiazine antipsychotics |
| US7196105B2 (en) * | 2002-06-24 | 2007-03-27 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
| LT1531794T (lt) * | 2002-06-28 | 2017-08-25 | Civitas Therapeutics, Inc. | Inhaliuojamas epinefrinas |
| WO2004006841A2 (en) * | 2002-07-12 | 2004-01-22 | University Of Rochester | Use of amino acids for treatment of various conditions |
| DK1567164T3 (da) * | 2002-11-26 | 2009-05-18 | Alexza Pharmaceuticals Inc | Anvendelse af loxapin til fremstilling af et lægemiddel til behandling af smerte |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
| JP2006516963A (ja) * | 2003-02-04 | 2006-07-13 | クリサリス テクノロジーズ インコーポレイテッド | エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出 |
| EP1617820B1 (en) | 2003-04-14 | 2018-03-21 | Vectura Limited | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| US20040234699A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| US7954491B2 (en) * | 2003-06-13 | 2011-06-07 | Civitas Therapeutics, Inc. | Low dose pharmaceutical powders for inhalations |
| WO2005020958A2 (en) * | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
| US7462646B2 (en) | 2003-08-26 | 2008-12-09 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| CA2570976C (en) | 2004-06-18 | 2013-08-13 | Novartis Vaccines And Diagnostics, Inc. | Methods of treatment of endobronchial infections |
| CA2576961A1 (en) | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| JP5307397B2 (ja) | 2004-09-18 | 2013-10-02 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法 |
| JP5085326B2 (ja) | 2004-09-18 | 2012-11-28 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法 |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US20060134009A1 (en) * | 2004-12-16 | 2006-06-22 | Daniel Deaver | Low dose corticosteroid powders for inhalation |
| PL1883665T3 (pl) | 2005-04-22 | 2018-05-30 | Universite De Geneve | Kompozycje polilaktydowe i ich zastosowania |
| IN2014DN09128A (enExample) | 2005-09-14 | 2015-07-10 | Mannkind Corp | |
| CN101389348A (zh) | 2006-02-22 | 2009-03-18 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
| US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| EP2120580B1 (en) | 2007-02-02 | 2017-12-27 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| CA2618099C (en) | 2007-02-09 | 2016-09-20 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
| ES2538082T3 (es) | 2007-02-11 | 2015-06-17 | Map Pharmaceuticals Inc | Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| WO2009002832A2 (en) | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
| US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN109568740B (zh) | 2008-06-13 | 2022-05-27 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
| BR122020002400B1 (pt) | 2008-06-20 | 2021-12-07 | Mannkind Corporation | Sistema de detecção de inalação de pó seco e sistema de monitoramento acoplável para um inalador de pó seco |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| SG193801A1 (en) * | 2008-08-15 | 2013-10-30 | Ironwood Pharmaceuticals Inc | Linaclotide-containing formulations for oral administration |
| WO2010031054A1 (en) * | 2008-09-15 | 2010-03-18 | Biovista, Inc. | Compositions and methods for treating epilepsy |
| EP2719380A3 (en) | 2008-09-16 | 2014-07-30 | University of Maryland, Baltimore | SUR1 inhibitors for therapy |
| US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| PL2405963T3 (pl) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Urządzenie, układ i sposób pomiaru oporu inhalatora |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| RU2577698C2 (ru) | 2009-03-26 | 2016-03-20 | Пулмэтрикс, Инк. | Сухие порошкообразные составы и способы лечения легочных заболеваний |
| WO2010124276A2 (en) | 2009-04-24 | 2010-10-28 | Vanderbilt Universtiy | Anti-tgf-beta induction of bone cell function and bone growth |
| CA2764505C (en) | 2009-06-12 | 2018-09-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US8748573B2 (en) * | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
| DK2536742T3 (en) | 2010-02-17 | 2017-09-04 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
| US20140005128A1 (en) | 2010-08-11 | 2014-01-02 | Forest Laboratories Holdings Limited | Treatments of gastrointestinal disorders |
| EP3192880B1 (en) | 2010-08-18 | 2019-10-09 | Fred Hutchinson Cancer Research Center | Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd) |
| WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| CA2812414C (en) | 2010-09-29 | 2020-09-22 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
| JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| ES2751388T3 (es) | 2011-07-22 | 2020-03-31 | Univ Chicago | IGF-1 para su uso en el tratamiento de la jaqueca |
| MX347354B (es) | 2011-08-17 | 2017-04-24 | Ironwood Pharmaceuticals Inc | Tratamientos para trastornos gastrointestinales. |
| US9655905B2 (en) | 2011-09-14 | 2017-05-23 | King Abdullah University Of Science And Technology | Treatment of sickle cell disease |
| US9644005B2 (en) | 2011-09-21 | 2017-05-09 | King Abdullah University Of Science And Technology | Didemnin biosynthetic gene cluster in Tistrella mobilis |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| EP2852413A4 (en) | 2012-02-16 | 2016-04-27 | Univ Toledo | XENOANTIGEN WITH VACCINES AGAINST CANCER AND MANUFACTURING PROCESS THEREFOR |
| US20150018362A1 (en) | 2012-02-27 | 2015-01-15 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
| JP2015509788A (ja) | 2012-02-29 | 2015-04-02 | パルマトリックス，インコーポレイテッド | 吸入に適した乾燥粉末 |
| AR092821A1 (es) | 2012-04-20 | 2015-05-06 | Sucampo Ag | Conjugado de derivado de acido graso-polimero |
| MX353567B (es) | 2012-05-23 | 2018-01-18 | Univ Ohio State | Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido. |
| CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| EP2887944B1 (en) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| NZ747373A (en) * | 2012-10-22 | 2020-02-28 | Civitas Therapeutics Inc | Reducing inter-patient variability of levodopa plasma concentrations |
| CN104884046A (zh) | 2012-10-22 | 2015-09-02 | 丝维塔斯治疗公司 | 用于快速缓解帕金森病的左旋多巴制剂 |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| US8545878B1 (en) * | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
| WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| AU2013352141B2 (en) | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| FR3000392B1 (fr) * | 2012-12-27 | 2015-03-27 | Virbac | Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation |
| US10208012B2 (en) | 2013-03-13 | 2019-02-19 | Board Of Regents, The University Of Texas System | Compounds for treating inflammatory and hyperproliferative diseases |
| MX392016B (es) | 2013-03-15 | 2025-03-21 | Mannkind Corp | Composiciones de dicetopiperazina microcristalina y métodos. |
| PL2978482T3 (pl) * | 2013-03-26 | 2022-10-03 | Optinose As | Podawanie donosowe |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| EP2981247B1 (en) | 2013-04-01 | 2023-06-07 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| HK1218855A1 (zh) * | 2013-04-30 | 2017-03-17 | Otitopic Inc. | 干粉製劑及使用方法 |
| EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
| NZ720311A (en) | 2013-12-02 | 2022-10-28 | Baylor College Medicine | Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose |
| EP4119131A1 (en) | 2014-02-20 | 2023-01-18 | Otitopic Inc. | Dry powder formulations for inhalation |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| WO2015157500A1 (en) | 2014-04-09 | 2015-10-15 | Research Development Foundation | Class iia hdac inhibitors for the treatment of infection |
| CN106659685B (zh) * | 2014-04-21 | 2021-02-05 | 丝维塔斯治疗公司 | 快速减轻帕金森病中的运动波动 |
| WO2016025202A1 (en) | 2014-08-14 | 2016-02-18 | The Regents Of The University Of Colorado | Antibody-sirna conjugates and uses therefor |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| MX392636B (es) | 2014-10-31 | 2025-03-24 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
| WO2016073184A1 (en) | 2014-11-04 | 2016-05-12 | Dana Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| WO2016172026A1 (en) | 2015-04-20 | 2016-10-27 | The Board Of Regents Of The University Of Texas System | Clec11a is a bone growth agent |
| EP3288591A1 (en) * | 2015-05-01 | 2018-03-07 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
| WO2016205615A1 (en) | 2015-06-17 | 2016-12-22 | The Johns Hopkins University | Tdp-43 in degenerative disease |
| EP3316865A4 (en) | 2015-07-02 | 2019-01-23 | Civitas Therapeutics, Inc. | TRIPTAN POWDER FOR PULMONARY ADMINISTRATION |
| US10695322B2 (en) | 2016-01-29 | 2020-06-30 | The Johns Hopkins University | Inhibitors of bacterial growth |
| US11040025B2 (en) | 2016-02-17 | 2021-06-22 | The Johns Hopkins University | Oxazolidinone for treatment of infections with Mycobacterium tuberculosis |
| WO2017147370A1 (en) | 2016-02-24 | 2017-08-31 | The Johns Hopkins University | Novel antiviral proteins and their uses in therapeutic methods |
| US10888549B2 (en) | 2016-03-07 | 2021-01-12 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
| CA3158448A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3426785A4 (en) | 2016-03-10 | 2019-12-25 | The Johns Hopkins University | METHOD FOR PRODUCING AGGREGATE-FREE MONOMER DIPHTHERIETOXINFUSION PROTEINS AND THERAPEUTIC USES |
| US11203626B2 (en) | 2016-03-10 | 2021-12-21 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
| WO2017161155A1 (en) | 2016-03-17 | 2017-09-21 | The Johns Hopkins University | Methods for preventing or treating parkinson's disease by the farnesylation of paris |
| EP3436609B1 (en) | 2016-03-30 | 2022-05-04 | The Johns Hopkins University | Olfr90 specificity and methods of detection |
| WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
| US10568894B2 (en) | 2016-06-03 | 2020-02-25 | Otitopic Inc. | Dry powder formulations for inhalation |
| US11149275B2 (en) | 2016-10-10 | 2021-10-19 | The Johns Hopkins University | Device and method to treat esophageal disorders |
| MX393985B (es) | 2016-12-09 | 2025-03-24 | Alexza Pharmaceuticals Inc | Metodo para el tratamiento de la epilepsia |
| US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
| EP3595642A4 (en) | 2017-03-14 | 2021-05-26 | Baylor College of Medicine | DOMINANT ACTIVE YAP, A HIPPO EFFECTOR, FOR INDUCING CHROMATINE ACCESSIBILITY AND CARDIOMYOCYTE REFRESHMENT |
| US11892457B2 (en) | 2017-07-12 | 2024-02-06 | The Johns Hopkins University | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| WO2019059953A2 (en) | 2017-09-22 | 2019-03-28 | Otitopic Inc. | DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE |
| US20200330541A1 (en) | 2017-11-16 | 2020-10-22 | University Of Maine System Board Of Trustees | Compositions and methods for modulating endothelial cell migration and angiogenesis |
| US11246857B2 (en) | 2017-12-14 | 2022-02-15 | The Johns Hopkins University | Anti-fungal inhibitors |
| CA3090277A1 (en) | 2018-02-02 | 2019-08-08 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| EP3762401A4 (en) | 2018-03-06 | 2021-12-08 | The Johns Hopkins University | CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR |
| US11771685B2 (en) | 2018-07-29 | 2023-10-03 | Musc Foundation For Research Development | Compounds for the treatment of neurological or mitochondrial diseases |
| WO2020033130A1 (en) | 2018-08-06 | 2020-02-13 | The Johns Hopkins University | Treatment of irritable bowel syndrome with molybdenum |
| CN113166241B (zh) | 2018-08-16 | 2025-02-25 | 约翰霍普金斯大学 | 人类znt8抗体 |
| EP3921029B1 (en) | 2019-02-07 | 2025-07-30 | Baylor College of Medicine | Composition comprising ccl5 for use in treating bone break, bone fracture, bone degeneration and osteoporosis |
| US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
| US12366570B2 (en) | 2019-10-01 | 2025-07-22 | The Johns Hopkins University | Cell-based ZNT8 assay |
| EP4081222A4 (en) | 2019-12-26 | 2023-11-01 | Figene, LLC | PREVENTION AND TREATMENT OF KIDNEY FAILURE BY ADMINISTRATION OF FIBROBLASTS AND PRODUCTS THEREOF |
| EP4081227A4 (en) | 2019-12-26 | 2023-11-29 | Figene, LLC | Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof |
| EP4114379A4 (en) | 2020-03-04 | 2024-01-17 | Pleopharma, L.L.C. | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND ALLEVIATING THE SYMPTOMS OF CANNABINOID WITHDRAWAL |
| WO2022087270A1 (en) | 2020-10-23 | 2022-04-28 | Mirati Therapeutics, Inc. | Methods for treatment of lung cancers |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| JPS6122019A (ja) | 1984-07-06 | 1986-01-30 | Tomio Konno | 吸入細胞活性薬品とその使用方法 |
| GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| EP0223831B1 (en) | 1985-05-22 | 1992-07-15 | Liposome Technology, Inc. | Liposome inhalation method and system |
| AU601176B2 (en) * | 1986-03-10 | 1990-09-06 | Kurt Burghart | Benzodiazepine aerosols |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
| US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| WO1991016882A1 (en) | 1990-05-08 | 1991-11-14 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
| US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
| GB9101592D0 (en) | 1991-01-24 | 1991-03-06 | Glaxo Group Ltd | Compositions |
| ATE179605T1 (de) * | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | Antireaktive antiasthmatische wirkung von acetylsalicylsäure durch inhalation |
| EP0533268B1 (en) | 1991-09-18 | 2001-08-16 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
| US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
| WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| ES2316917T3 (es) | 1994-03-07 | 2009-04-16 | Nektar Therapeutics | Metodos y composiciones para suministro pulmonar de insulina. |
| CA2190502A1 (en) * | 1994-05-18 | 1995-11-23 | Robert M. Platz | Methods and compositions for the dry powder formulation of interferons |
| CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6503480B1 (en) * | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6103270A (en) | 1996-06-07 | 2000-08-15 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5958902A (en) | 1997-04-16 | 1999-09-28 | Wisconsin Alumni Research Foundation | Method and composition for treating sleep apnea |
| US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| HK1048956B (zh) | 1999-05-27 | 2006-07-28 | 阿库斯菲尔公司 | 多孔药物基质及其制造方法 |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| WO2002094243A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
-
2001
- 2001-06-08 US US09/877,734 patent/US6613308B2/en not_active Expired - Lifetime
- 2001-09-19 EP EP01971210.8A patent/EP1318785B1/en not_active Expired - Lifetime
- 2001-09-19 CA CA2421974A patent/CA2421974C/en not_active Expired - Lifetime
- 2001-09-19 DK DK01971210.8T patent/DK1318785T3/en active
- 2001-09-19 JP JP2002528195A patent/JP5421510B2/ja not_active Expired - Lifetime
- 2001-09-19 WO PCT/US2001/029311 patent/WO2002024158A2/en not_active Ceased
- 2001-09-19 AU AU9112201A patent/AU9112201A/xx active Pending
- 2001-09-19 ES ES01971210.8T patent/ES2621549T3/es not_active Expired - Lifetime
- 2001-09-19 PT PT1971210T patent/PT1318785T/pt unknown
- 2001-09-19 AU AU2001291122A patent/AU2001291122B2/en not_active Expired
- 2001-09-19 EP EP15201016.1A patent/EP3061453A1/en not_active Ceased
-
2003
- 2003-05-20 US US10/441,968 patent/US6979437B2/en not_active Expired - Lifetime
-
2004
- 2004-01-21 US US10/762,200 patent/US20040228923A1/en not_active Abandoned
- 2004-07-21 US US10/895,577 patent/US20040265242A1/en not_active Abandoned
-
2008
- 2008-07-02 US US12/166,704 patent/US20090162441A1/en not_active Abandoned
-
2011
- 2011-09-13 US US13/231,405 patent/US20120087952A1/en not_active Abandoned
-
2012
- 2012-06-27 JP JP2012144071A patent/JP2012180378A/ja not_active Withdrawn
-
2014
- 2014-01-10 US US14/152,492 patent/US20140193501A1/en not_active Abandoned
-
2017
- 2017-03-21 CY CY20171100358T patent/CY1118851T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3061453A1 (en) | 2016-08-31 |
| US20140193501A1 (en) | 2014-07-10 |
| CA2421974A1 (en) | 2002-03-28 |
| US20040228923A1 (en) | 2004-11-18 |
| CA2421974C (en) | 2011-03-29 |
| US20090162441A1 (en) | 2009-06-25 |
| PT1318785T (pt) | 2017-04-19 |
| JP2004509141A (ja) | 2004-03-25 |
| US20120087952A1 (en) | 2012-04-12 |
| US20030235537A1 (en) | 2003-12-25 |
| ES2621549T3 (es) | 2017-07-04 |
| US20040265242A1 (en) | 2004-12-30 |
| US6979437B2 (en) | 2005-12-27 |
| EP1318785B1 (en) | 2016-12-21 |
| JP5421510B2 (ja) | 2014-02-19 |
| EP1318785A2 (en) | 2003-06-18 |
| US20020058009A1 (en) | 2002-05-16 |
| AU9112201A (en) | 2002-04-02 |
| WO2002024158A3 (en) | 2002-09-19 |
| WO2002024158A8 (en) | 2003-02-20 |
| CY1118851T1 (el) | 2018-01-10 |
| WO2002024158A2 (en) | 2002-03-28 |
| JP2012180378A (ja) | 2012-09-20 |
| AU2001291122B2 (en) | 2005-03-10 |
| US6613308B2 (en) | 2003-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1318785T3 (en) | PULMONAL ADMINISTRATION OF L-DOPA | |
| US6514482B1 (en) | Pulmonary delivery in treating disorders of the central nervous system | |
| AU2001291122A1 (en) | Pulmonary delivery in treating disorders of the central nervous system | |
| US8586093B2 (en) | Pulmonary delivery for levodopa | |
| US7556798B2 (en) | Highly efficient delivery of a large therapeutic mass aerosol | |
| EP1345629A2 (en) | Particles for inhalation having sustained release properties | |
| AU2002230993A1 (en) | Particles for inhalation having sustained release properties | |
| HK1051139B (en) | Highly efficient delivery of a large therapeutic mass aerosol | |
| HK1098078A (en) | Highly efficient delivery of a large therapeutic mass aerosol |